<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Article Tag Suite 1.1//EN"
  "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:mml="http://www.w3.org/1998/Math/MathML"
         article-type="research-article"
         xml:lang="en">
  <front>
    <journal-meta>
      <journal-title-group>
        <journal-title>American Journal of PharmTech Research</journal-title>
        <abbrev-journal-title abbrev-type="publisher">AJPTR</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="epub">2249-3387</issn>
      <publisher>
        <publisher-name>undefined</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">AJPTR63014</article-id>
      <title-group>
        <article-title>Potentiality of a newer oral Anti hyperglycemic combination therapy over conventional therapy in type 2  diabetes</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>V.Satyanarayana</surname>
            <given-names>V.Satyanarayana</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gunda</surname>
            <given-names>Raghavendra Kumar</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kumar</surname>
            <given-names>J.N.Suresh</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rani</surname>
            <given-names>G.Swarupa</given-names>
          </name>
        </contrib>
      </contrib-group>
      <pub-date pub-type="epub" iso-8601-date="2016-06-01">
        <month>06</month>
        <day>01</day>
        <year>2016</year>
      </pub-date>
      <volume>6</volume>
      <issue>3</issue>
      <abstract>
        <p>Over the last decade, diabetes mellitus has emerged as an important clinical and public health problem throughout the world. The aim of the study is   perceive the Potentiality of a newer oral Antihyperglycemic combination therapy over conventional therapy in type 2 diabetes. The prospective study was conducted over a period of six months in the department of Medicine, Guntur City Hospital. The prevalence of type2 diabetes was high in male 65.79 % than female 34.21%. Majority of the patients  (23.68 %) belonged to age group of 51–55 years. Majority of patients (55.26%) having a family history of Diabetes. Majority of patients receiving Combination of Glibenclamide + Metformin (60.53%), evaluated for effect on FPG for both combinations. The mean changes in FPG were noted. In the same way effect on HbA1c also noted. Mean changes in for every month HbA1c will be noted. Our study reveals that Combination therapy with Metformin plus Glimepiride is more effective than Glibenclamide plus Metformin; in improving glycemic control in type 2 diabetes, while also allowing a reduction of the dosage of each drug.</p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <kwd>Diabetes Mellitus</kwd>
        <kwd>ADA</kwd>
        <kwd>HbA1c</kwd>
        <kwd>FPG</kwd>
        <kwd>Glibenclamide</kwd>
        <kwd>Metformin</kwd>
        <kwd>Glimepiride.</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <!-- Full article body not available in metadata-only JATS export. See PDF/HTML galley. -->
  </body>
  <back/>
</article>
